BC
MRSN

Bridgefront Capital’s Mersana Therapeutics MRSN Stock Holding History

Bridgefront Capital’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-625
Closed -$97K – 373
2021
Q4 		$97K Buy
+625
New +$122K 0.09% 272
2021
Q3 		– Sell
-449
Closed -$153K – 559
2021
Q2 		$153K Buy
+449
New +$170K 0.06% 529

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Bridgefront Capital's MRSN Position: Q1 2022 in Review

Bridgefront Capital sold out of Mersana Therapeutics (MRSN) in Q1 2022, closing a stake of 625 shares — an estimated $97K sold.

Bridgefront Capital first reported a position in MRSN in Q2 2021 and held it in 2 quarters. The position peaked at $153K in Q2 2021. 129 funds tracked by Wall St. Rank hold MRSN as of Q1 2022.

  • Bridgefront Capital reported no remaining Mersana Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Bridgefront Capital sold 625 Mersana Therapeutics shares in Q1 2022, an estimated $97K.
  • Bridgefront Capital first reported a position in Mersana Therapeutics in Q2 2021 and held it in 2 quarters.
  • Bridgefront Capital's Mersana Therapeutics position peaked at $153K in Q2 2021.
  • 129 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2022.

Based on Bridgefront Capital's 13F filing for Q1 2022, filed 13 May 2022.